University of Vienna
Latest From University of Vienna
The USPTO's PTAB will determine whether UC-Berkeley or Broad Institute holders of CRISPR patents first invented its use in eukaryotic cells. The outcome could either benefit the Berkeley group, which could simplify licensing deals, or maintain the status quo.
Despite being ineligible to license its CRISPR technology for human gene and cell therapy applications, ERS is doing considerable business with biopharmas for internal R&D projects.
With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.
Three CRISPR/Cas9 patent owners and four companies that license the intellectual property – CRISPR, Intellia, Caribou and ERS – signed a formal agreement to protect their patent rights and cross-license necessary IP while a patent interference proceeding is ongoing.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.